Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Revatio
Revatio 10 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 45
HOS-115058 · Präparat HOS-094193
The most potent of the CYP3A4 inhibitors such as ketoconazole and itraconazole would be expected
to have effects similar to ritonavir (see section 4.3). CYP3A4 inhibitors like clarithromycin,
telithromycin and nefazodone are expected to have an effect in between that of ritonavir and CYP3A4
inhibitors like saquinavir or erythromycin, a seven-fold increase in exposure is assumed. Therefore
dose adjustments are recommended when using CYP3A4 inhibitors (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) ketoconazole (HOS-084513) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:12:00Z · SHA-256 38afb4f2877b63c9a3d5213ff8cb4458ff9d43618600f9ce01caed1bd5a4764f · Passage 1f4082a0a6c5d963b63edd22c10b5845b86bc5ff94e6467a165f0531de78d7d3 · Zeichen 4968–5440 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-116681 · Präparat HOS-094467
Active substances that may increase dasatinib plasma concentrations
In vitro studies indicate that dasatinib is a CYP3A4 substrate. Concomitant use of dasatinib and
medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole,
erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to
dasatinib. Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4
inhibitor is not recommended (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) grapefruit juice (HOS-088787) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 4b7cd825bd806fe7cb0d08d7e8a48b7de39787bee3636b13d11149364312873c · Zeichen 0–506 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 47
HOS-116736 · Präparat HOS-094467
Active substances that may increase dasatinib plasma concentrations
In vitro studies indicate that dasatinib is a CYP3A4 substrate. Concomitant use of dasatinib and
medicinal products or substances which potently inhibit CYP3A4 (e.g. ketoconazole, itraconazole,
erythromycin, clarithromycin, ritonavir, telithromycin, grapefruit juice) may increase exposure to
dasatinib. Therefore, in patients receiving dasatinib, systemic administration of a potent CYP3A4
inhibitor is not recommended (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) grapefruit juice (HOS-088787) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 4b7cd825bd806fe7cb0d08d7e8a48b7de39787bee3636b13d11149364312873c · Zeichen 0–506 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Toviaz
TOVIAZ 4 mg prolonged-release tablets TOVIAZ 8 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117260 · Präparat HOS-094561
Potent CYP3A4 inhibitors
Following inhibition of CYP3A4 by co-administration of ketoconazole 200 mg twice daily, Cmax and
AUC of the active metabolite of fesoterodine increased 2.0 and 2.3-fold in CYP2D6 extensive
metabolisers and 2.1 and 2.5-fold in CYP2D6 poor metabolisers, respectively. Therefore, the
maximum dose of fesoterodine should be restricted to 4 mg when used concomitantly with potent
CYP3A4 inhibitors (e.g. atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone,
nelfinavir, ritonavir (and all ritonavir boosted PI-regimens), saquinavir and telithromycin (see
sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) ketoconazole (HOS-084513) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-04T15:52:00Z · SHA-256 c9fd9fb2f6c8ee3d5e56c913ba09d40147211dee6df16329539fa6b5e813accb · Passage 679ac7be8f845fe7a62693f49c65460a286580b97dd43cc2c87699cd8e06bb99 · Zeichen 898–1520 im Abschnitt
Wechselwirkungen · Ivemend
IVEMEND 150 mg powder for solution for infusion. · Abschnitt 4.5 · PDF-Seite 8–9
HOS-117455 · Präparat HOS-094609
8
Effect of other medicinal products on the pharmacokinetics of aprepitant resulting from administration
of fosaprepitant 150 mg
Concomitant administration of fosaprepitant with active substances that inhibit CYP3A4 activity
(e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin,
nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected
to result in several-fold increased plasma concentrations of aprepitant (see section 4.4). Ketoconazole
increased the terminal half-life of oral aprepitant about 3-fold.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) protease (HOS-085623) ketoconazole (HOS-084513) aprepitant (HOS-112506) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage 7ce7d41e2ab0f0ac1b8f4133034740037037d4a9df6bf48423bebc9306343d60 · Zeichen 7311–7901 im Abschnitt
Wechselwirkungen · Rasilez
Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-208748 · Präparat HOS-154177
Moderate P-gp inhibitors
Co-administration of ketoconazole (200 mg) or verapamil (240 mg) with aliskiren (300 mg) resulted in
a 76% or 97% increase in aliskiren AUC, respectively. The change in plasma levels of aliskiren in the
presence of ketoconazole or verapamil is expected to be within the range that would be achieved if the
dose of aliskiren were doubled; aliskiren doses of up to 600 mg, or twice the highest recommended
therapeutic dose, have been found to be well tolerated in controlled clinical studies. Preclinical studies
indicate that aliskiren and ketoconazole co-administration enhances aliskiren gastrointestinal
absorption and decreases biliary excretion. Therefore, caution should be exercised when aliskiren is
administered with ketoconazole, verapamil or other moderate P-gp inhibitors (clarithromycin,
telithromycin, erythromycin, amiodarone).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) telithromycin (HOS-084523) clarithromycin (HOS-084517) erythromycin (HOS-084514) amiodarone (HOS-085596) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T02:00:00Z · SHA-256 4518ee1f6936dd9da7c06dbb3fa8bed38b206400f5cb767391af486f27614e43 · Passage 8898f8394fd7b9bda1795a62be6f4d74c4d349adaa142a9c153d5288c323bb5c · Zeichen 3098–3964 im Abschnitt
Wechselwirkungen · Tyverb
Tyverb 250 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-208920 · Präparat HOS-154213
In healthy volunteers receiving ketoconazole, a strong CYP3A4 inhibitor, at 200 mg twice daily for
7 days, systemic exposure to lapatinib (100 mg daily) was increased approximately 3.6–fold, and
half-life increased 1.7–fold. Co-administration of Tyverb with strong inhibitors of CYP3A4 (e.g.
ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole,
nefazodone) should be avoided. Co-administration of Tyverb with moderate inhibitors of CYP3A4
should proceed with caution and clinical adverse reactions should be carefully monitored.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-06T15:40:00Z · SHA-256 cc5bd96641c0b3f4003ec76839196782d898a5b2fc432b1735c84b65f7171b92 · Passage caf653bb8bf77066a4a3bd16cfe29398b83a2f480fc6af93e07911d6d5eefa4f · Zeichen 118–687 im Abschnitt
Wechselwirkungen · Tasigna
Tasigna 50 mg hard capsules Tasigna 150 mg hard capsules Tasigna 200 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-118202 · Präparat HOS-094783
10
The exposure to nilotinib in healthy subjects was increased 3-fold when co-administered with the
strong CYP3A4 inhibitor ketoconazole. Concomitant treatment with strong CYP3A4 inhibitors,
including ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, and telithromycin,
should therefore be avoided (see section 4.4). Increased exposure to nilotinib might also be expected
with moderate CYP3A4 inhibitors. Alternative concomitant medicinal products with no or minimal
CYP3A4 inhibition should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-17T17:21:00Z · SHA-256 efb2ca2c5c7d9a0e740759217e71ff7f08cf3763f8c41f5c02f5d10733d67b3a · Passage aba926163dfe081ecdf5d7d5fd37f48c0c3219fed062f1dfbe4cda3086c034c8 · Zeichen 1026–1552 im Abschnitt
Gegenanzeigen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-118245 · Präparat HOS-094791
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Severe renal impairment (creatinine clearance < 30 ml/min) (see sections 4.2 and 5.2).
Moderate or severe hepatic impairment (see sections 4.2 and 5.2).
Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole,
voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone) (see
sections 4.2 and 4.5).
Concomitant administration of Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol)
antiarrhythmics other than amiodarone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) sotalol (HOS-085597) protease (HOS-085623) ketoconazole (HOS-084513) dofetilide (HOS-085598) quinidine (HOS-085593) creatinine (HOS-086273) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) amiodarone (HOS-085596) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage e965caed4195dcdfd3678bb06e75f92bc1c9af65dda5f0db39fdeffc5ef9a1bb · Zeichen 0–592 im Abschnitt
Gegenanzeigen · Ranexa (previously Latixa)
Ranexa 500 mg prolonged-release tablets · Abschnitt 4.3 · PDF-Seite 15
HOS-118293 · Präparat HOS-094791
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Severe renal impairment (creatinine clearance < 30 ml/min) (see sections 4.2 and 5.2).
Moderate or severe hepatic impairment (see sections 4.2 and 5.2).
Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole,
voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone) (see
sections 4.2 and 4.5).
Concomitant administration of Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol)
antiarrhythmics other than amiodarone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) sotalol (HOS-085597) protease (HOS-085623) ketoconazole (HOS-084513) dofetilide (HOS-085598) quinidine (HOS-085593) creatinine (HOS-086273) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) amiodarone (HOS-085596) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage e965caed4195dcdfd3678bb06e75f92bc1c9af65dda5f0db39fdeffc5ef9a1bb · Zeichen 0–592 im Abschnitt
Gegenanzeigen · Ranexa (previously Latixa)
Ranexa 750 mg prolonged-release tablets · Abschnitt 4.3 · PDF-Seite 27
HOS-118335 · Präparat HOS-094791
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Severe renal impairment (creatinine clearance < 30 ml/min) (see sections 4.2 and 5.2).
Moderate or severe hepatic impairment (see sections 4.2 and 5.2).
Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole,
voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone) (see
sections 4.2 and 4.5).
Concomitant administration of Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol)
antiarrhythmics other than amiodarone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) sotalol (HOS-085597) protease (HOS-085623) ketoconazole (HOS-084513) dofetilide (HOS-085598) quinidine (HOS-085593) creatinine (HOS-086273) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) amiodarone (HOS-085596) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage e965caed4195dcdfd3678bb06e75f92bc1c9af65dda5f0db39fdeffc5ef9a1bb · Zeichen 0–592 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-118248 · Präparat HOS-094791
CYP3A4 or P-gp inhibitors: Ranolazine is a substrate of cytochrome CYP3A4. Inhibitors of CYP3A4
increase plasma concentrations of ranolazine. The potential for dose-related adverse events (e.g.
nausea, dizziness) may also increase with increased plasma concentrations. Concomitant treatment
with ketoconazole 200 mg twice daily increased the AUC of ranolazine by 3.0- to 3.9-fold during
ranolazine treatment. Combining ranolazine with potent CYP3A4 inhibitors (e.g. itraconazole,
ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin,
nefazodone) is contraindicated (see section 4.3). Grapefruit juice is also a potent CYP3A4 inhibitor.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) protease (HOS-085623) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 5b3aa0003b70ce5744d5ae59ca13d0e5228e23b0fd7556d568afb76481af6bf0 · Zeichen 51–730 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 500 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-118295 · Präparat HOS-094791
CYP3A4 or P-gp inhibitors: Ranolazine is a substrate of cytochrome CYP3A4. Inhibitors of CYP3A4
increase plasma concentrations of ranolazine. The potential for dose-related adverse events (e.g.
nausea, dizziness) may also increase with increased plasma concentrations. Concomitant treatment
with ketoconazole 200 mg twice daily increased the AUC of ranolazine by 3.0- to 3.9-fold during
ranolazine treatment. Combining ranolazine with potent CYP3A4 inhibitors (e.g. itraconazole,
ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin,
nefazodone) is contraindicated (see section 4.3). Grapefruit juice is also a potent CYP3A4 inhibitor.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) protease (HOS-085623) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 5b3aa0003b70ce5744d5ae59ca13d0e5228e23b0fd7556d568afb76481af6bf0 · Zeichen 51–730 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 750 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-118337 · Präparat HOS-094791
CYP3A4 or P-gp inhibitors: Ranolazine is a substrate of cytochrome CYP3A4. Inhibitors of CYP3A4
increase plasma concentrations of ranolazine. The potential for dose-related adverse events (e.g.
nausea, dizziness) may also increase with increased plasma concentrations. Concomitant treatment
with ketoconazole 200 mg twice daily increased the AUC of ranolazine by 3.0- to 3.9-fold during
ranolazine treatment. Combining ranolazine with potent CYP3A4 inhibitors (e.g. itraconazole,
ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin,
nefazodone) is contraindicated (see section 4.3). Grapefruit juice is also a potent CYP3A4 inhibitor.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nefazodone (HOS-084519) protease (HOS-085623) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 5b3aa0003b70ce5744d5ae59ca13d0e5228e23b0fd7556d568afb76481af6bf0 · Zeichen 51–730 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-118469 · Präparat HOS-094825
Concomitant use of
CELSENTRI and
fosamprenavir/ritonavir is
not recommended.
Clarithromycin, Not studied, but both are potent CELSENTRI dose should
Telithromycin CYP3A4 inhibitors and would be be decreased to 150 mg
expected to increase maraviroc twice daily when
concentrations. co-administered with
clarithromycin and
telithromycin.
ANTICONVULSANTS
Carbamezepine, Not studied, but these are potent CELSENTRI dose should
Phenobarbital, CYP3A4 inducers and would be be increased to 600 mg
Phenytoin expected to decrease maraviroc twice daily when co-
concentrations. administered with
carbamazepine,
phenobarbital or
phenytoin in the absence
of a potent CYP3A4
inhibitor.
ANTIFUNGALS
Ketoconazole 400 mg QD Maraviroc AUCtau: ↑ 5.00 CELSENTRI dose should
(maraviroc 100 mg BID) Maraviroc Cmax: ↑ 3.38 be decreased to 150 mg
Ketoconazole concentrations not twice daily when
measured, no effect is expected. co-administered with
ketoconazole.
Itraconazole Not studied. Itraconazole, is a potent CELSENTRI dose should
CYP3A4 inhibitor and would be be decreased to 150 mg
expected to increase the exposure of twice daily when
maraviroc. co-administered with
itraconazole.
Fluconazole Fluconazole is considered to be a CELSENTRI 300 mg
moderate CYP3A4 inhibitor. twice daily should be
Population PK studies suggest that a administered with caution
dose adjustment of maraviroc is not when co-administered
required. with fluconazole.
ANTIVIRALS
Anti-HBV
Pegylated interferon Pegylated interferon has not been CELSENTRI 300 mg
studied, no interaction is expected. twice daily and pegylated
interferon can be
co-administered without
dose adjustment.
Anti-HCV
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) telithromycin (HOS-084523) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1d5347b247b278d8c4adf916ef615f4e2f029d5988565ee48d79ce9fbe1e5087 · Zeichen 17223–20590 im Abschnitt
Wechselwirkungen · Celsentri
CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 37–38
HOS-118508 · Präparat HOS-094825
Ritonavir AUC12: ↔ 0.93
Ritonavir Cmax: ↔ 1.02
Ritonavir C12: ↓ 0.74
Etravirine and Not studied. Based on the extent of
lopinavir/ritonavir, inhibition by lopinavir/ritonavir,
saquinavir/ritonavir or saquinavir/ritonavir or
atazanavir/ritonavir atazanavir/ritonavir in the absence of
etravirine, an increased exposure is
expected.
ANTIBIOTICS
37
Sulphamethoxazole/ Maraviroc AUC12: ↔ 1.11 CELSENTRI 300 mg twice
Trimethoprim Maraviroc Cmax: ↔ 1.19 daily and sulphamethoxazole/
800 mg/160 mg BID Sulphamethoxazole/trimethoprim trimethoprim can be
(maraviroc 300 mg BID) concentrations not measured, no co-administered without dose
effect expected. adjustment.
Rifampicin 600 mg QD Maraviroc AUC: ↓ 0.37 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.34 increased to 600 mg twice
Rifampicin concentrations not daily when co-administered
measured, no effect expected. with rifampicin in the absence
of a potent CYP3A4 inhibitor.
This dose adjustment has not
been studied in HIV patients.
See also section 4.4.
Rifampicin + efavirenz Combination with two inducers has Concomitant use of
not been studied. There may be a risk CELSENTRI and rifampicin
of suboptimal levels with risk of loss + efavirenz is not
of virologic response and resistance recommended.
development.
Rifabutin + PI Not studied. Rifabutin is considered CELSENTRI dose should be
to be a weaker inducer than decreased to 150 mg twice
rifampicin. When combining rifabutin daily when co-administered
with protease inhibitors that are with rifabutin and a PI
potent inhibitors of CYP3A4 a net (except tipranavir/ritonavir
inhibitory effect on maraviroc is where the dose should be 300
expected. mg twice daily). See also
section 4.4.
Concomitant use of
CELSENTRI and
fosamprenavir/ritonavir is not
recommended.
Clarithromycin, Not studied, but both are potent CELSENTRI dose should be
Telithromycin CYP3A4 inhibitors and would be decreased to 150 mg twice
expected to increase maraviroc daily when co-administered
concentrations. with clarithromycin and
telithromycin.
ANTICONVULSANTS
Carbamezepine, Not studied, but these are potent CELSENTRI dose should be
Phenobarbital, CYP3A4 inducers and would be increased to 600 mg twice
Phenytoin expected to decrease maraviroc daily when co-administered
concentrations. with carbamazepine,
phenobarbital or phenytoin in
the absence of a potent
CYP3A4 inhibitor.
ANTIFUNGALS
Ketoconazole 400 mg QD Maraviroc AUCtau: ↑ 5.00 CELSENTRI dose should be
(maraviroc 100 mg BID) Maraviroc Cmax: ↑ 3.38 decreased to 150 mg twice
Ketoconazole concentrations not daily when co-administered
measured, no effect is expected. with ketoconazole.
Itraconazole Not studied. Itraconazole, is a potent CELSENTRI dose should be
CYP3A4 inhibitor and would be decreased to 150 mg twice
expected to increase the exposure of daily when co-administered
maraviroc. with itraconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) trimethoprim (HOS-085184) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) rifabutin (HOS-086262) etravirine (HOS-088088) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) efavirenz (HOS-087947) fosamprenavir (HOS-086182) ritonavir (HOS-084521) phenytoin (HOS-084531) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1b627b7cd1e4efc3a8fc8f7680c5fda5526614bbd2d1f72d7ed1fca6f8314992 · Zeichen 13851–18833 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Efient
Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-120775 · Präparat HOS-095209
Inhibitors of CYP3A:
Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4 and CYP3A5, did not affect
prasugrel-mediated inhibition of platelet aggregation or the prasugrel active metabolite’s AUC and
Tmax, but decreased the Cmax by 34% to 46%. Therefore, CYP3A inhibitors such as azol antifungals,
HIV protease inhibitors, clarithromycin, telithromycin, verapamil, diltiazem, indinavir, ciprofloxacin,
and grapefruit juice are not anticipated to have a significant effect on the pharmacokinetics of the
active metabolite.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) protease (HOS-085623) ciprofloxacin (HOS-085177) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) telithromycin (HOS-084523) clarithromycin (HOS-084517) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-22T14:15:00Z · SHA-256 bf0eaa99dea4480cd15ea241fb41ce985dc8e97851472df117f97dc0c795a95e · Passage c575bf610302710cfcda171888cb81be40ebe235dc41e06b6aeed5676196eca7 · Zeichen 2949–3489 im Abschnitt
Wechselwirkungen · Iressa
IRESSA 250 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-121313 · Präparat HOS-095327
Active substances that may increase gefitinib plasma concentrations
In vitro studies have shown that gefitinib is a substrate of p-glycoprotein (Pgp). Available data do not
suggest any clinical consequences to this in vitro finding.
Substances that inhibit CYP3A4 may decrease the clearance of gefitinib. Concomitant administration
with potent inhibitors of CYP3A4 activity (e.g. ketoconazole, posaconazole, voriconazole, protease
inhibitors, clarithromycin, telithromycin) may increase gefitinib plasma concentrations. The increase
may be clinically relevant since adverse reactions are related to dose and exposure. The increase might
be higher in individual patients with CYP2D6 poor metaboliser genotype. Pre-treatment with
itraconazole (a potent CYP3A4 inhibitor) resulted in an 80% increase in the mean AUC of gefitinib in
healthy volunteers. In situations of concomitant treatment with potent inhibitors of CYP3A4 the
patient should be closely monitored for gefitinib adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-07-17T11:35:00Z · SHA-256 3bcaef596cdab500a720486bec050bfa038a5c9ed552c9e5d531667fcd7af63e · Passage b281fa0e088c702a732c816ca30646230c4a3c01a1b53971d51d7d95bdf98657 · Zeichen 105–1099 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.